Effects of a Non Thermal Plasma Treatment Alone or in Combination with Gemcitabine in a MIA PaCa2-luc Orthotopic Pancreatic Carcinoma Model

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Brullé, Laura ^a,b   Vandamme, Marc ^a,c,d   Riès, Delphine ^c   Martel, Eric ^b   Robert, Eric ^c   Lerondel, Stéphanie ^a   Trichet, Valérie ^c   Richard, Serge ^b   Pouvesle, Jean Michel ^c   Le Pape, Alain ^a,c  

^a C D T A Centre de Developpement de Techniques Avancees pour l'Experimentation Animale   (France)

^b Chemin de Montifault   (France)

^c Universite de Nantes   (France)

^d GERMITEC SAS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PLASMA GAS; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRACKING; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUCIFERASES, FIREFLY; MICE; PANCREATIC NEOPLASMS; PLASMA GASES; TUMOR BURDEN; WHOLE BODY IMAGING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871581171     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052653     Document Type: Article

References (44)

1. Vandamme M, Robert E, Pesnel S, Barbosa E, Dozias S, et al. (2010) Antitumor Effect of Plasma Treatment on U87 Glioma Xenografts: Preliminary Results. Plasma processes and polymers 7: 264-273.
2. Robert E, Barbosa E, Dozias S, Vandamme M, Cachoncinlle C, et al. (2009) Experimental Study of a Compact Nanosecond Plasma Gun. Plasma processes and polymers 6: 795-802.
3. Vandamme M, Robert E, Lerondel S, Sarron V, Ries D, et al. (2011) ROS implication in a new antitumor strategy based on non-thermal plasma. Int J Cancer.
4. Keidar M, Walk R, Shashurin A, Srinivasan P, Sandler A, et al. (2011) Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy. Br J Cancer 105: 1295-1301.
5. Vandamme M, Robert E, Dozias S, Sobilo J, Lerondel S, et al. (2011) Response of Human Glioma U87 Xenografted on Mice to Non Thermal Plasma Treatment. Plasma Medicine 1: 27-43.
6. Georgescu N, Lupu AR, (2010) Tumoral and Normal Cells Treatment With High-Voltage Pulsed Cold Atmospheric Plasma Jets. IEEE Transactions on Plasma Science 38: 1949-1955.
7. Wescott MP, Rustgi AK, (2008) Pancreatic Cancer: Translating Lessons from Mouse Models and Hereditary Syndromes. Cancer Prevention Research 1: 503-506.
8. Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, et al. (2000) Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 48: 919-922.
9. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, et al. (2003) The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4: 133-146.
10. Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, et al. (2003) A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. Journal of Surgical Research 113: 151-160.
11. Milas L, Fujii T, Hunter N, Elshaikh M, Mason K, et al. (1999) Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Research 59: 107-114.
12. Yunis AA, Arimura GK, Russin DJ, (1977) HUMAN PANCREATIC CARCINOMA (MIA PACA-2) IN CONTINUOUS CULTURE- SENSITIVITY TO ASPARAGINASE. International Journal of Cancer 19: 128-135.
13. Rousseau J, Escriou V, Perrot P, Picarda G, Charrier C, et al. (2010) Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Therapy 17: 387-397.
14. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, et al. (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human imunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Human Gene Therapy 13: 803-813.
15. Qin XF, An DS, Chen ISY, Baltimore D, (2003) Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proceedings of the National Academy of Sciences of the United States of America 100: 183-188.
16. Pauwels B, Korst AEC, Lardon F, Vermorken JB, (2005) Combined modality therapy of gemcitabine and radiation. Oncologist 10: 34-51.
17. Dobrynin D, Fridman G, Friedman G, Fridman A (2009) Physical and biological mechanisms of direct plasma interaction with living tissue. New Journal of Physics 11.
18. Fridman G, Friedman G, Gutsol A, Shekhter AB, Vasilets VN, et al. (2008) Applied plasma medicine. Plasma Processes and Polymers 5: 503-533.
19. Kim JY, Wei YZ, Li JH, Foy P, Hawkins T, et al. (2011) Single-Cell-Level Microplasma Cancer Therapy. Small 7: 2291-2295.
20. Kim CH, Kwon S, Bahn JH, Lee K, Jun SI, et al. (2010) Effects of atmospheric nonthermal plasma on invasion of colorectal cancer cells. Applied Physics Letters 96.
21. Kalghatgi S, Kelly CM, Cerchar E, Torabi B, Alekseev O, et al. (2011) Effects of non-thermal plasma on Mammalian cells. PLoS One 6: e16270.
22. Lopez-Lazaro M, (2007) Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett 252: 1-8.
23. Bornmann C, Graeser R, Esser N, Ziroli V, Jantscheff P, et al. (2008) A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging. Cancer Chemotherapy and Pharmacology 61: 395-405.
24. Zagon IS, Jaglowski JR, Verderame MF, Smith JP, Leure-duPree AE, et al. (2005) Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology 56: 510-520.
25. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M, (2004) Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clinical Cancer Research 10: 2936-2943.
26. Tseng WW, Winer D, Kenkel JA, Choi O, Shain AH, et al. (2010) Development of an Orthotopic Model of Invasive Pancreatic Cancer in an Immunocompetent Murine Host. Clinical Cancer Research 16: 3684-3695.
27. Bouvet M, Hoffman RM, (2009) Clinically-relevent orthotopic metastatic models of pancreatic cancer imageable with fluorescent genetic reporters. Minerva Chirurgica 64: 521-539.
28. Mees G, Dierckx R, Vangestel C, Van de Wiele C, (2009) Molecular imaging of hypoxia with radiolabelled agents. European Journal of Nuclear Medicine and Molecular Imaging 36: 1674-1686.
29. Saif MW, Brennan M, Penney R, Hotchkiss S, Kaley K, (2011) Cutaneous metastasis in a patient with pancreatic cancer. JOP: Journal of the pancreas 12: 306-308.
30. Zhao H, Zhu J, Cui K, Xu X, O'Brien M, et al. (2009) Bioluminescence imaging reveals inhibition of tumor cell proliferation by Alzheimer's amyloid beta protein. Cancer Cell International 9.
31. Wilson KD, Huang M, Wu JC, (2009) Bioluminescence Reporter Gene Imaging of Human Embryonic Stem Cell Survival, Proliferation, and Fate. Bioluminescence: Methods and Protocols, Second Edition 574: 87-103.
32. Buchler P, Reber HA, Lavey RS, Tomlinson J, Buchler MW, et al. (2004) Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. Journal of Surgical Research 120: 295-303.
33. Okano K, Kakinoki K, Akamoto S, Hagiike M, Usuki H, et al. (2011) (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World Journal of Gastroenterology 17: 231-235.
34. Buchs NC, Buehler L, Bucher P, Willi J-P, Frossard J-L, et al. (2011) Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: A prospective study. Journal of Gastroenterology and Hepatology 26: 657-662.
35. Hessenius C, Bader M, Meinhold H, Bohmig M, Faiss S, et al. (2000) Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours. European Journal of Nuclear Medicine 27: 1684-1693.
36. Varvarigou A, Bouziotis P, Zikos C, Scopinaro F, De Vincentis G, (2004) Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biotherapy and Radiopharmaceuticals 19: 219-229.
37. Schottelius M, Laufer B, Kessler H, Wester H-J, (2009) Ligands for Mapping alpha(v)beta(3)-Integrin Expression in Vivo. Accounts of Chemical Research 42: 969-980.
38. Shewach DS, Lawrence TS, (1996) Gemcitabine and radiosensitization in human tumor cells. Investigational New Drugs 14: 257-263.
39. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS, (1996) Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. International Journal of Radiation Oncology Biology Physics 34: 867-872.
40. Cardillo TM, Blumenthal R, Ying ZL, Gold DV, (2002) Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. International Journal of Cancer 97: 386-392.
41. Yip-Schneider MT, Sweeney CJ, Jung SH, Crowell PL, Marshall MS, (2001) Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. Journal of Pharmacology and Experimental Therapeutics 298: 976-985.
42. Kim CH, Bahn JH, Lee SH, Kim GY, Jun SI, et al. (2010) Induction of cell growth arrest by atmospheric non-thermal plasma in colorectal cancer cells. J Biotechnol.
43. Yan X, Zou F, Zhao S, Lu X, He G, et al. (2010) On the Mechanism of Plasma Inducing Cell Apoptosis. IEEE Transactions on Plasma Science 38: 2451-2457.
44. Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, et al. (1998) Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro. International Journal of Radiation Oncology Biology Physics 41: 875-882.